Dynavax Technologies Corporation

10/18/2021 | Press release | Distributed by Public on 10/18/2021 00:33

COVID-19 Vaccine Developed by Valneva Using Dynavax's CpG 1018 Adjuvant Meets Both Co-Primary Endpoints in Phase 3 COV-COMPARE Trial